Kidney Transplantation-Pipeline Review, H1 2015

Kidney Transplantation-Pipeline Review, H1 2015

  • Products Id :- GMDHC6534IDB
  • |
  • Pages: 148
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Kidney Transplantation-Pipeline Review, H1 2015


Global Markets Direct's, 'Kidney Transplantation-Pipeline Review, H1 2015', provides an overview of the Kidney Transplantation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Transplantation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Kidney Transplantation and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Kidney Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Kidney Transplantation pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Kidney Transplantation Overview 10

Therapeutics Development 11

Pipeline Products for Kidney Transplantation-Overview 11

Pipeline Products for Kidney Transplantation-Comparative Analysis 12

Kidney Transplantation-Therapeutics under Development by Companies 13

Kidney Transplantation-Therapeutics under Investigation by Universities/Institutes 15

Kidney Transplantation-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Kidney Transplantation-Products under Development by Companies 20

Kidney Transplantation-Products under Investigation by Universities/Institutes 22

Kidney Transplantation-Companies Involved in Therapeutics Development 23

Alexion Pharmaceuticals, Inc. 23

Angion Biomedica Corp. 24

Astellas Pharma Inc. 25

Bio-inRen 26

CSL Limited 27

Digna Biotech, S.L. 28

Effimune SAS 29

GlaxoSmithKline plc 30

Grifols, S.A. 31

Hansa Medical AB 32

Kyowa Hakko Kirin Co., Ltd. 33

Novartis AG 34

Onyx Pharmaceuticals, Inc. 35

Opsona Therapeutics Ltd. 36

Pharmicell Co., Ltd. 37

Pharming Group N.V. 38

Quark Pharmaceuticals, Inc. 39

Shire Plc 40

t-cell Europe GmbH 41

Tolera Therapeutics, Inc. 42

Kidney Transplantation-Therapeutics Assessment 43

Assessment by Monotherapy Products 43

Assessment by Target 44

Assessment by Mechanism of Action 46

Assessment by Route of Administration 48

Assessment by Molecule Type 50

Drug Profiles 52

albumin (human)-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

AS-2521780-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ASKP-1240-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

BB-3-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

belimumab-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

BRN-1889-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

C1 esterase inhibitor (human)-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

C1 esterase inhibitor (human)-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

C1 esterase inhibitor (recombinant)-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

cardiotrophin-1-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

carfilzomib-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Cell Therapy for Kidney Transplantation-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

Cell Therapy for Kidney Transplantation-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

CFZ-533-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

eculizumab-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

EFFI-7H-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

ETR-002-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

FCR-001-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

foralumab-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

FX-06-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

IgG-Degrading Enzyme of Streptococcus pyogenes-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Immucellgram-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

OPN-305-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

QPI-1002-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

T-Cell Therapy for Kidney Transplant-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

TOL-101-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

voclosporin-Drug Profile 102

Product Description 102

Mechanism of Action 102

R&D Progress 102

Kidney Transplantation-Recent Pipeline Updates 105

Kidney Transplantation-Dormant Projects 135

Kidney Transplantation-Discontinued Products 137

Kidney Transplantation-Product Development Milestones 138

Featured News & Press Releases 138

May 14, 2015: Angion Biomedica Advances BB3 into Pivotal Phase 3 Clinical Trial in Renal Transplant Patients with Delayed Graft Function 138

May 06, 2015: Hansa Medical Establishes a US medical advisory board for IdeS in kidney transplantation 139

Apr 13, 2015: Alexion Announces Presentations at 2015 American Transplant Congress, Including Results from Studies Advancing the Understanding of Eculizumab (Soliris) in Patients Undergoing Kidney Transplant 140

Feb 12, 2015: Hansa Medical develops second-generation IdeS molecules for repeat dosing 141

Feb 05, 2015: Hansa Medical announces cooperation with Cedars-Sinai Medical Center's Comprehensive Transplant Center and US transplantation expert Stanley Jordan 141

Jan 20, 2015: Successful Phase 2 Study of IdeS in Highly Sensitized Dialysis Patients awaiting Kidney Transplantation 142

Jan 07, 2015: Alexion Provides Update on Phase 2 Clinical Trial with Eculizumab in Antibody Mediated Rejection (AMR) in Living-Donor Kidney Transplant Recipients 142

Aug 25, 2014: Alexion Initiates Multinational Registration Trial of Eculizumab for the Prevention of Delayed Graft Function (DGF) after Kidney Transplantation 143

Aug 18, 2014: The Hansa Medical candidate drug IdeS has enabled successful kidney transplantation 144

Jul 28, 2014: Quark Pharmaceuticals Reports Favorable Results From Phase II Clinical Trial Evaluating Investigational siRNA QPI-1002 145

Appendix 147

Methodology 147

Coverage 147

Secondary Research 147

Primary Research 147

Expert Panel Validation 147

Contact Us 147

Disclaimer 148

List of Tables

Number of Products under Development for Kidney Transplantation, H1 2015 11

Number of Products under Development for Kidney Transplantation-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Development by Companies, H1 2015 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H1 2015 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Comparative Analysis by Unknown Stage Development, H1 2015 19

Products under Development by Companies, H1 2015 20

Products under Development by Companies, H1 2015 (Contd..1) 21

Products under Investigation by Universities/Institutes, H1 2015 22

Kidney Transplantation-Pipeline by Alexion Pharmaceuticals, Inc., H1 2015 23

Kidney Transplantation-Pipeline by Angion Biomedica Corp., H1 2015 24

Kidney Transplantation-Pipeline by Astellas Pharma Inc., H1 2015 25

Kidney Transplantation-Pipeline by Bio-inRen, H1 2015 26

Kidney Transplantation-Pipeline by CSL Limited, H1 2015 27

Kidney Transplantation-Pipeline by Digna Biotech, S.L., H1 2015 28

Kidney Transplantation-Pipeline by Effimune SAS, H1 2015 29

Kidney Transplantation-Pipeline by GlaxoSmithKline plc, H1 2015 30

Kidney Transplantation-Pipeline by Grifols, S.A., H1 2015 31

Kidney Transplantation-Pipeline by Hansa Medical AB, H1 2015 32

Kidney Transplantation-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 33

Kidney Transplantation-Pipeline by Novartis AG, H1 2015 34

Kidney Transplantation-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 35

Kidney Transplantation-Pipeline by Opsona Therapeutics Ltd., H1 2015 36

Kidney Transplantation-Pipeline by Pharmicell Co., Ltd., H1 2015 37

Kidney Transplantation-Pipeline by Pharming Group N.V., H1 2015 38

Kidney Transplantation-Pipeline by Quark Pharmaceuticals, Inc., H1 2015 39

Kidney Transplantation-Pipeline by Shire Plc, H1 2015 40

Kidney Transplantation-Pipeline by t-cell Europe GmbH, H1 2015 41

Kidney Transplantation-Pipeline by Tolera Therapeutics, Inc., H1 2015 42

Assessment by Monotherapy Products, H1 2015 43

Number of Products by Stage and Target, H1 2015 45

Number of Products by Stage and Mechanism of Action, H1 2015 47

Number of Products by Stage and Route of Administration, H1 2015 49

Number of Products by Stage and Molecule Type, H1 2015 51

Kidney Transplantation Therapeutics-Recent Pipeline Updates, H1 2015 105

Kidney Transplantation-Dormant Projects, H1 2015 135

Kidney Transplantation-Dormant Projects (Contd..1), H1 2015 136

Kidney Transplantation-Discontinued Products, H1 2015 137

List of Figures

Number of Products under Development for Kidney Transplantation, H1 2015 11

Number of Products under Development for Kidney Transplantation-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 43

Number of Products by Top 10 Targets, H1 2015 44

Number of Products by Stage and Top 10 Targets, H1 2015 44

Number of Products by Top 10 Mechanism of Actions, H1 2015 46

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 46

Number of Products by Top 10 Routes of Administration, H1 2015 48

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 49

Number of Products by Top 10 Molecule Types, H1 2015 50

Number of Products by Stage and Top 10 Molecule Types, H1 2015 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Alexion Pharmaceuticals, Inc.

Angion Biomedica Corp.

Astellas Pharma Inc.


CSL Limited

Digna Biotech, S.L.

Effimune SAS

GlaxoSmithKline plc

Grifols, S.A.

Hansa Medical AB

Kyowa Hakko Kirin Co., Ltd.

Novartis AG

Onyx Pharmaceuticals, Inc.

Opsona Therapeutics Ltd.

Pharmicell Co., Ltd.

Pharming Group N.V.

Quark Pharmaceuticals, Inc.

Shire Plc

t-cell Europe GmbH

Tolera Therapeutics, Inc.

Kidney Transplantation Therapeutic Products under Development, Key Players in Kidney Transplantation Therapeutics, Kidney Transplantation Pipeline Overview, Kidney Transplantation Pipeline, Kidney Transplantation Pipeline Assessment

select a license

Single User License
USD 2000 INR 135980
Site License
USD 4000 INR 271960
Corporate User License
USD 6000 INR 407940



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]